BioGaia ABBGLAF 100 Return-on-Tangible-Asset is 21.20% as of Mar. 2026, which is 8% above its 10-year median of 19.58. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.52 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, BioGaia AB ranks better than 95.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioGaia AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $34.1 Mil. BioGaia AB's average total tangible assets for the quarter that ended in Mar. 2026 was $160.8 Mil. Therefore, BioGaia AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 21.20%.
The historical rank and industry rank for BioGaia AB's Return-on-Tangible-Asset or its related term are showing as below:
BGLAF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 10.36 Med: 19.58 Max: 48.12
Current: 22.19
During the past 13 years, BioGaia AB's highest Return-on-Tangible-Asset was 48.12%. The lowest was 10.36%. And the median was 19.58%.
BGLAF's Return-on-Tangible-Asset is ranked better than 95.42% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs BGLAF: 22.19
BioGaia AB (OTCPK:BGLAF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioGaia AB Return-on-Tangible-Asset Related Terms
BioGaia AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 21.20% mean?
BioGaia AB (BGLAF) has a Return-on-Tangible-Asset of 21.20% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioGaia AB and its competitors. This is near median its historical median of 19.58. Over the past decade, BioGaia AB's Return-on-Tangible-Asset has ranged from 10.36 to 48.12. According to the industry distribution chart, BioGaia AB ranks #46 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is BioGaia AB's Return-on-Tangible-Asset too high?
BioGaia AB's current Return-on-Tangible-Asset of 21.20% is near median its 10-year median of 19.58. Over the past 10 years, this metric has ranged from a low of 10.36 to a high of 48.12. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. BioGaia AB's value of 21.20% is 573% above this industry median. Based on the distribution chart, BioGaia AB ranks #46 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #46 out of 1005 companies for Return-on-Tangible-Asset. This places BioGaia AB in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. BioGaia AB's value of 21.20% is 573% above this benchmark. Historically, BioGaia AB's own Return-on-Tangible-Asset has ranged from 10.36 to 48.12 over the past decade. While the company's 10-year median is 19.58 vs. the industry median of 3.15, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Return-on-Tangible-Asset of 21.20% is 573% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Return-on-Tangible-Asset is 21.20%, which is near median its own 10-year median of 19.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.52, compared to a current price of $12.20 — trading 2.6% below its estimated fair value. The current Return-on-Tangible-Asset is 21.20%, which is near median its 10-year median of 19.58 and 573% above the Drug Manufacturers industry median of 3.15. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Return-on-Tangible-Asset is 21.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.6% below its estimated GF Value™ of $12.52.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Return-on-Tangible-Asset: 21.20% (near median its 10-year median of 19.58)
GF Value™: $12.52 vs. price of $12.20 (2.6% below fair value)
Industry Position: 573% above the Drug Manufacturers median (#46 of 1005)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
